Hansa Medical begins IdeS dosing in Phase II trial for anti-GBM antibody disease

Swedish biopharmaceutical firm Hansa Medical has begun dosing patients in its Phase II clinical trial of drug candidate IgG degrading enzyme of Streptococcus pyogenes (IdeS), to treat patients with severe anti-GBM antibody disease / Goodpasture ’s dis…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news